

Supplementary information

Materials and methods

All chemicals were purchased from *Sigma Aldrich Co.* (Steinheim, Germany) and were used without further purification. All solvents were dried and distilled before use. The purity of all compounds was checked by thin-layer chromatography (TLC-plates; *Merck*, Darmstadt, Germany) using silica gel 60 F₂₅₄ plates (*Merck*) and common eluents. The plates were visualized under UV (254 nm) light or by usage of Bromothymol Blue. Purification of the products was carried out by recrystallization or by middle pressure liquid chromatography (MPLC; *Büchi*, Essen, Germany) on silica gel (0.040–0.063 mm, *Merck*). The MPLC was equipped with a Fraction Collector C-660, Pump Module C-601 (2×), Pump Manager C-615 and UV detector (cut off = 254 nm).

Melting points were determined with a Boetius apparatus. NMR spectra were recorded with either a 400 MHz spectrometer (Varian Gemini 2000) operating at 400 MHz for ¹H nuclei and 100 MHz for ¹³C nuclei or a 500 MHz spectrometer (Varian Inova 500) operating at 500 MHz for ¹H nuclei and 125 MHz for ¹³C nuclei. All chemical shifts are reported in parts per million (ppm) relative to CHCl₃ at ¹H-NMR (δ = 7.24 ppm) and at ¹³C-NMR (δ = 77.00 ppm), respectively. ¹H-NMR spectroscopic data are reported as chemical shift, relative integral, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad signals), coupling constant (*J* in Hz) and assignment. Mass spectrometric data were obtained with a Finnigan mass spectrometer model MAT SSQ 710 C (ESI-MS) or were recorded on an AMD 402 (70 eV) spectrometer (EI-MS). Elemental analyses were recorded on a Leco CHNS-932. High resolution mass spectrometry (HR-MS) was performed using a LTQ-Orbitrap mass spectrometer with static nano-electrospray ionization (nano-ESI, positive modus) and a *m/z* range from 150 to 2000 (resolution: 30000). The mass spectrometric data were evaluated using XCalibur 2.0.7 software.

Et₂PE-C32-Et₂PE

The synthesis of dotriacontane-1,32-diyl-bis[2-(diethylammonio)ethylphosphate] (Et₂PE-C32-Et₂PE) was carried out applying the general phosphorylation and quarternisation procedure of long-chain 1, ω -diols as described previously^{S1} using 0.5 mmol of dotriacontane-1,32-diol (0.24 g).^{S1}

Yield: 0.17 g (41%); ¹H-NMR (500 MHz, CDCl₃/CD₃OD, 27 °C): δ = 1.22–1.28 (m, 56 H, –O(CH₂)₂(CH₂)₂₈(CH₂)₂O–), 1.32 (t, ³J_{H,H} = 7.3 Hz, 12 H, 4× –CH₂CH₃), 1.57–1.63 (m, 4 H, –OCH₂CH₂(CH₂)₂₈CH₂CH₂O–), 3.14 (q, ³J_{H,H} = 7.3 Hz, 8 H, 4× –CH₂CH₃), 3.23–3.25 (m, 4 H, 2× NCH₂CH₂O–), 3.83 („q“, *J* = 6.7 Hz, 4 H, –OCH₂(CH₂)₃₀CH₂O–), 4.07–4.11 ppm (m, 4 H, 2× NCH₂CH₂O–); MS (ESI): *m/z*: 839.7 [M – H][–], 842.0 [M + H]⁺, 863.6 [M + Na]⁺, 1703.8 [2M + Na]⁺; elemental analysis calcd. (%) for C₄₄H₉₄N₂O₈P₂ × 3H₂O: C 59.03, H 11.26, N 3.13; found: 58.86, H 11.11, N 3.11.

PC-C32Me₂-PC

The synthesis of 10,23-dimethyldotriacontane-1,32-diyl-bis[2-(trimethylammonio)ethylphosphate] (PC-C32Me₂-PC) was carried out applying the general

phosphorylation and quarternisation procedure of long-chain 1, ω -diols as described previously^{S1} using 0.5 mmol of the methyl-modified diol (0.255 g).^{S2}

Yield: 0.22 g (53%); R_f = 0.24 (CHCl₃/MeOH/NH₃ = 10/10/3); ¹H-NMR (500 MHz, CDCl₃/CD₃OD, 27 °C): δ = 0.55 (d, ³ $J_{H,H}$ = 6.6 Hz, 6 H, 2 \times -CHCH₃), 0.76–0.81 (m, 4 H, 2 \times -CHHCH(CH₃)CHH-), 0.97–1.08 (m, 50 H, -CH₂-, -CH-), 1.31–1.37 (m, 4 H, 2 \times -OCH₂CH₂(CH₂)₇-), 2.93 (s, 18 H, 2 \times -N(CH₃)₃), 3.31–3.33 (m, 4 H, 2 \times NCH₂CH₂O-), 3.56–3.60 („q“, J = 6.7 Hz, 4 H, 2 \times -OCH₂(CH₂)₈-), 3.92–3.98 ppm (m, 4 H, 2 \times NCH₂CH₂O-); ¹³C-NMR (125 MHz, CDCl₃/CD₃OD, 27 °C): δ = 10 18.99 (-CHCH₃), 25.27 (2 \times -O(CH₂)₂CH₂-), 26.54 and 26.57 (2 \times -CH₂CH₂CH(CH₃)CH₂CH₂-), 28.88, 29.13, 29.16, 29.47 and 29.51 (-CH₂-), 30.25 (d, ³ $J_{C,P}$ = 7.3 Hz, 2 \times -OCH₂CH₂(CH₂)₇-), 32.25 (-CH-), 36.59 and 36.60 (2 \times -CH₂CH(CH₃)CH₂-), 53.51 (t, J = 3.8 Hz, 2 \times -N(CH₃)₃), 58.47 (d, ² $J_{C,P}$ = 5 Hz, 2 \times NCH₂CH₂O-), 65.55 (d, ² $J_{C,P}$ = 6 Hz, 2 \times -OCH₂(CH₂)₈-), 65.93 ppm (b, 2 \times 15 NCH₂CH₂O-); MS (ESI): m/z : 841.34 [M + H]⁺, 863.25 [M + Na]⁺, 1703.76 [2M + Na]⁺; HR-MS (C₄₄H₉₄N₂O₈P₂): m/z : [M + H]⁺ exp. 841.6558, calc. 841.6558.

Me₂PE-C32Me₂-Me₂PE

The synthesis of 10,23-dimethyldotriacontane-1,32-diyl-bis[2-(dimethylammonio)ethylphosphate] (Me₂PE-C32Me₂-Me₂PE) was carried out applying the general 20 phosphorylation and quarternisation procedure of long-chain 1, ω -diols as described previously^{S1} using 0.5 mmol of the methyl-modified diol (0.255 g).^{S2}

Yield: 0.27 g (67%); ¹H-NMR (500 MHz, CDCl₃/CD₃OD, 27 °C): δ = 0.69 (d, ³ $J_{H,H}$ = 6.6 Hz, 6 H, 2 \times -CHCH₃), 0.91–0.94 (m, 4 H, 2 \times -CHHCH(CH₃)CHH-), 1.12– 25 1.22 (m, 50 H, -CH₂-, -CH-), 1.47–1.53 (m, 4 H, 2 \times -OCH₂CH₂(CH₂)₇-), 2.76 (s, 12 H, 2 \times -N(CH₃)₂), 3.17–3.18 (m, 4 H, 2 \times NCH₂CH₂O-), 3.75–3.79 („q“, J = 6.7 Hz, 4 H, 2 \times -OCH₂(CH₂)₈-), 4.03–4.07 ppm (m, 4 H, 2 \times NCH₂CH₂O-); ¹³C-NMR (125 MHz, CDCl₃/CD₃OD, 27 °C): δ = 19.41 (-CHCH₃), 25.42 (2 \times -O(CH₂)₂CH₂-), 26.76 and 26.82 (2 \times -CH₂CH₂CH(CH₃)CH₂CH₂-), 29.07, 29.33, 30 29.37, 29.41, 29.69 and 29.75 (-CH₂-), 30.34 (d, ³ $J_{C,P}$ = 6.9 Hz, 2 \times -OCH₂CH₂(CH₂)₇-), 32.47 (-CH-), 36.79 and 36.82 (2 \times -CH₂CH(CH₃)CH₂-), 43.03 (2 \times -N(CH₃)₂), 58.31 (d, $J_{C,P}$ = 5.5 Hz) and 59.15 (d, $J_{C,P}$ = 5.0 Hz, 2 \times NCH₂CH₂O-), 66.53 ppm (d, ² $J_{C,P}$ = 6.0 Hz, 2 \times -OCH₂(CH₂)₈-); MS (ESI): m/z : 35 811.52 [M - H]⁻, 813.34 [M + H]⁺, 835.20 [M + Na]⁺, 1647.23 [2M + Na]⁺; HR-MS (C₄₂H₉₀N₂O₈P₂): m/z : [M + H]⁺ exp. 813.62213, calc. 813.62452.

PC-C32Ac-PC

The synthesis of dotriacont-16-in-1,32-diyl-bis[2-(trimethylammonio)ethylphosphate] (PC-C32Ac-PC) was carried out applying the general phosphorylation and quarternisation procedure of long-chain 1, ω -diols as described previously^{S1} using 40 0.2 mmol of the acetylene-modified diol (95 mg), which was isolated during the synthesis of diacetylene-modified diols.^{S3}

Yield: 65 mg (40%); R_f = 0.27 (CHCl₃/MeOH/NH₃ = 10/10/3); ¹H-NMR (400 MHz, CDCl₃/CD₃OD, 27 °C): δ = 1.15–1.29 (m, 44 H, 2 \times -OCH₂CH₂(CH₂)₁₁CH₂CH₂-), 45 1.33–1.39 (m, 4 H, -CH₂CH₂C \equiv CCH₂CH₂-), 1.48–1.54 (m, 4 H, 2 \times -OCH₂CH₂(CH₂)₁₃-), 2.03 („t“, J = 6.9 Hz, 4 H, -CH₂C \equiv CCH₂-), 3.12 (s, 18 H, 6 \times -CH₃), 3.53–3.55 (m, 4 H, 2 \times NCH₂CH₂O-), 3.76 („q“, J = 6.7 Hz, 4 H, 2 \times

$-\text{OCH}_2(\text{CH}_2)_{14}-$, 4.13–4.18 ppm (m, 4 H, $2\times \text{NCH}_2\text{CH}_2\text{O}-$); ^{13}C -NMR (100 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$, 27 °C): $\delta = 18.54$ ($-\text{CH}_2\text{C}\equiv\text{CCH}_2-$), 25.63 ($2\times -\text{O}(\text{CH}_2)_2\text{CH}_2(\text{CH}_2)_{12}-$), 28.61, 28.91, 29.03, 29.28, 29.46, 29.51, 29.53, 29.545, 29.575 and 29.582 ($2\times -\text{O}(\text{CH}_2)_3(\text{CH}_2)_{11}\text{CH}_2-$), 30.61 (d, $^3J_{\text{C,P}} = 7.4$ Hz, $2\times$ 5 $-\text{OCH}_2\text{CH}_2(\text{CH}_2)_{13}-$), 54.13 (t, $J = 3.7$ Hz, $6\times -\text{CH}_3$), 58.93 (d, $^2J_{\text{C,P}} = 5.1$ Hz, $2\times \text{NCH}_2\text{CH}_2\text{O}-$), 66.03 (d, $^2J_{\text{C,P}} = 6.0$ Hz, $2\times -\text{OCH}_2(\text{CH}_2)_{14}-$), 66.29 (b, $2\times \text{NCH}_2\text{CH}_2\text{O}-$), 80.22 ppm ($-\text{C}\equiv\text{C}-$); MS (ESI): m/z : 809.38 $[\text{M} + \text{H}]^+$, 831.12 $[\text{M} + \text{Na}]^+$, 1617.63 $[2\text{M} + \text{H}]^+$; HR-MS ($\text{C}_{42}\text{H}_{86}\text{N}_2\text{O}_8\text{P}_2$): m/z : $[\text{M} + \text{H}]^+$ exp. 809.5938, calc. 809.5932.

10

References

- (S1) Drescher, S.; Meister, A.; Blume, A.; Karlsson, G.; Almgren, M.; Dobner, B. *Chem. Eur. J.* 2007, **13**, 5300.
- (S2) Heiser, U. F.; Raik, W.; Dobner, B. *Chem. Phys. Lipids* 1997, **90**, 25.
- 15 (S3) Drescher, S.; Helmis, K.; Langner, A.; Dobner, B. *Monatsh. Chem.* 2010, **141**, 339.